» Articles » PMID: 38479817

Robust Positive Association Between Serum Urate and the Risk of Chronic Obstructive Pulmonary Disease: Hospital-based Cohort and Mendelian Randomisation Study

Overview
Date 2024 Mar 13
PMID 38479817
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic obstructive pulmonary disease (COPD) and hyperuricaemia are both characterised by systemic inflammation. Preventing chronic diseases among the population with common metabolic abnormality is an effective strategy. However, the association of hyperuricaemia with the higher incidence and risk of COPD remains controversial. Therefore, replicated researches in populations with distinct characteristics or demographics are compellingly warranted.

Methods: This cohort study adopted a design of ambispective hospital-based cohort. We used propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) to minimise the effects of potential confounding factors. A Cox regression model and restricted cubic spline (RCS) model were applied further to assess the effect of serum urate on the risk of developing COPD. Finally, we conducted a two-sample Mendelian randomisation (MR) analysis to explore evidence of causal association.

Results: There is a higher incidence in the population with hyperuricaemia compared with the population with normal serum urate (22.29/1000 person-years vs 8.89/1000 person-years, p=0.009). This result is robust after performing PSM (p=0.013) and IPTW (p<0.001). The Cox model confirms that hyperuricaemia is associated with higher risk of developing COPD (adjusted HR=3.35 and 95% CI=1.61 to 6.96). Moreover, RCS shows that the risk of developing COPD rapidly increases with the concentration of serum urate when it is higher than the reference (420 µmol/L). Finally, in MR analysis, the inverse variance weighted method evidences that a significant causal effect of serum urate on COPD (OR=1.153, 95% CI=1.034 to 1.289) is likely to be true. The finding of MR is robust in the repeated analysis using different methods and sensitivity analysis.

Conclusions: Our study provides convincing evidence suggesting a robust positive association between serum urate and the risk of developing COPD, and indicates that the population with hyperuricaemia is at high risk of COPD in the Chinese population who seek medical advice or treatment in the hospital.

Citing Articles

Enzyme Biosensor Based on 3D-Printed Flow-Through Reactor Modified with Thiacalixarene-Functionalized Oligo (Lactic Acids).

Stoikov D, Kappo D, Ivanov A, Gorbachuk V, Mostovaya O, Padnya P Biosensors (Basel). 2025; 15(2).

PMID: 39996979 PMC: 11852404. DOI: 10.3390/bios15020077.


Potential pharmacological effect of Quercetin Phytosome™ in the management of hyperuricemia: results from real-life clinical studies.

DI Pierro F, Rabbani F, Tareen M, Nigar R, Khan A, Zerbinati N Front Nutr. 2025; 12:1519459.

PMID: 39990611 PMC: 11844220. DOI: 10.3389/fnut.2025.1519459.


Hyperuricemia and its related diseases: mechanisms and advances in therapy.

Du L, Zong Y, Li H, Wang Q, Xie L, Yang B Signal Transduct Target Ther. 2024; 9(1):212.

PMID: 39191722 PMC: 11350024. DOI: 10.1038/s41392-024-01916-y.

References
1.
Braga T, Forni M, Correa-Costa M, Ramos R, Barbuto J, Branco P . Soluble Uric Acid Activates the NLRP3 Inflammasome. Sci Rep. 2017; 7:39884. PMC: 5233987. DOI: 10.1038/srep39884. View

2.
Fang L, Gao P, Bao H, Tang X, Wang B, Feng Y . Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018; 6(6):421-430. PMC: 7185405. DOI: 10.1016/S2213-2600(18)30103-6. View

3.
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J . Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237-41. DOI: 10.1038/nature04516. View

4.
van der Vliet A, ONeill C, Cross C, Koostra J, Volz W, Halliwell B . Determination of low-molecular-mass antioxidant concentrations in human respiratory tract lining fluids. Am J Physiol. 1999; 276(2):L289-96. DOI: 10.1152/ajplung.1999.276.2.L289. View

5.
. Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases. Chin Med J (Engl). 2017; 130(20):2473-2488. PMC: 5684625. DOI: 10.4103/0366-6999.216416. View